Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BTX-A51 |
Synonyms | |
Therapy Description |
BTX-A51 is a small molecule inhibitor of CSNK1A1, CDK7, and CDK9, which may lead to Tp53 stabilization and apoptotic induction, inhibition of colony formation, and antitumor activity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BTX-A51 | BTXA51 | CDK7 Inhibitor 16 CDK9 Inhibitor 21 | BTX-A51 is a small molecule inhibitor of CSNK1A1, CDK7, and CDK9, which may lead to Tp53 stabilization and apoptotic induction, inhibition of colony formation, and antitumor activity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04243785 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT06414434 | Phase I | BTX-A51 | BTX-A51 in Patients With Liposarcoma | Recruiting | USA | 0 |
NCT04872166 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | Recruiting | USA | 0 |